Experimental combo targets Hard-to-Treat blood cancers

NCT ID NCT02493530

Completed Disease control Sponsor: Vanderbilt-Ingram Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone or had never taken similar drugs. The study focused on safety and early signs of response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TGR-1202 (a PI3K delta inhibitor) combined with ruxolitinib
What this could lead to: If it works, this could offer a new combination option for patients with myelofibrosis or polycythemia vera who don't respond well to standard therapy.
What could go wrong: This is a very early Phase 1 trial with only 60 participants, focused on safety. It's too small and early to know if the combination is truly effective or safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera myelodysplastic/myeloproliferative neoplasm myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS POLYCYTHEMIA VERA

Contacts and locations

Show contact details

Locations

Mayo Clinic - Arizona

Phoenix, Arizona, 85054, United States
Mays Cancer Center at University of Texas Health San Antonio

San Antonio, Texas, 78229, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
University of Colorado Cancer Center

Aurora, Colorado, 80045, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.